Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.59 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437484 | 0.87 | MDM2 (0.54) | MDM2HCAR1CHRNA7KMO | |
| SCHEMBL9894128 | 0.80 | MDM2 (0.85) | MDM2CASP1KMO | |
| SCHEMBL1437294 | 0.80 | MDM2 (0.67) | MDM2CASP1GRIN1GRIN2BKMO | |
| SCHEMBL1436927 | 0.78 | MDM2 (0.75) | MDM2CASP1GRIN1GRIN2B | |
| SCHEMBL1437796 | 0.77 | MDM2 (0.47) | MDM2HCAR1TGFBR1TGFBR2GRIN1 | |
| SCHEMBL9894004 | 0.75 | MDM2 (0.67) | MDM2CASP1 | |
| SCHEMBL1437291 | 0.75 | MDM2 (0.70) | MDM2CASP1CHRNA7 | |
| SCHEMBL1438330 | 0.75 | MDM2 (0.67) | MDM2CASP1TGFBR1TGFBR2 | |
| SCHEMBL1436932 | 0.75 | MDM2 (0.61) | MDM2CASP1TGFBR1TGFBR2GRIN1 | |
| SCHEMBL1437289 | 0.75 | MDM2 (0.71) | MDM2TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885HCAR1 1812/4885CASP1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.